

First ColoSTAT® Clinical Test Sale — Commercial and Logistical Pathway Validated and Ready to Scale

Highlights

- ✓ Rhythm completes the first commercial sale of its blood based ColoSTAT® colorectal cancer test, marking the commencement of the Company's commercial clinical diagnostic testing operations.
- ✓ The full end-to-end clinical pathway — from blood draw at a collection site through to result delivery to the ordering clinician has now been successfully completed in a routine clinical setting.
- ✓ Immediate scale-up can now proceed directly with physicians and through the ColoSTAT® Access Program using a validated commercial and logistical pathway.

Melbourne, Australia, 11th March 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to report the first sale of the blood based ColoSTAT® colorectal cancer test for individuals with symptoms of colorectal cancer.

The first patient's blood samples have been collected by the Company's commercial partner, 4Cytte Pathology, transported to Rhythm's clinical laboratory in Parkville, VIC, processed using the ColoSTAT® assay, and results were reported to the ordering clinician. In this case, the clinic will be invoiced directly.

The successful completion of this first commercial clinical test confirms that the full operational pathway, including sample collection, logistics, assay processing, and result reporting are all functioning effectively within a routine clinical setting. This milestone validates that Rhythm's ColoSTAT® testing service can be integrated into existing clinical and pathology workflows and is a scalable revenue-generating testing service.

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

Scaling through direct physician contact and the ColoSTAT® Access Program

With the logistical pathway now validated, Rhythm will immediately expand test volumes directly through primary care physicians and through the ColoSTAT® Access Program (the **Program**), announced on 11th February 2026.

The Program provides a structured entry point for clinicians to begin ordering ColoSTAT® and for the Company to collect valuable clinical data, with 5 participating sites in VIC and NSW already onboarded ahead of this first test completion.

Rhythm's Managing Director and CEO, Dr. David Atkins, said: "The completion of the first commercial ColoSTAT® test sale is an important operational milestone for Rhythm. We have built a pathway that is practical for clinicians and seamless for patients, and today's result demonstrates that the full end-to-end process works as intended. We have the infrastructure, the logistics, and the partnerships in place to scale from here, and we look forward to reporting on test volume growth in the coming months."

The Company will provide updates on commercial progress and adoption rates through its regular quarterly reporting.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType[™]

geneType[™] is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.